Description
IGF‑1 LR3 (Long R3 Insulin‑Like Growth Factor‑1) is a synthetic analog of human IGF‑1. Two key changes—an arginine substitution at position 3 (R3) and a 13‑amino‑acid N‑terminal extension—lower its binding to IGF‑binding proteins (IGFBPs) and prolong its half‑life compared with native IGF‑1. IGF‑1 LR3 is not FDA‑approved. By contrast, mecasermin is the FDA‑approved form of recombinant IGF‑1 for severe primary IGF‑1 deficiency (not the LR3 analog).






There are no reviews yet.